FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 323:1009-1014 October 11, 1990 Number 15 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. The initially tested dose of zidovudine for the treatment of patients with advanced disease caused by the human immunodeficiency virus type 1 (HIV) was 1500 mg. Although this dose is effective, it is associated with substantial toxicity. METHODS. To evaluate the efficacy and safety of a reduced dose, we conducted a randomized controlled trial in 524 subjects who had had a first episode of Pneumocystis carinii pneumonia. The subjects were assigned to receive zidovudine in either a dose of 250 mg taken orally every four hours (the standard-treatment group, n = 262) or a dose of 200 mg taken orally every four hours for four weeks and thereafter 100 mg taken every four hours (the low-dose group, n = 262). RESULTS. The median length of follow-up was 25.6 months. At 18 months the estimated survival rates were 52 percent for the standard-treatment group and 63 percent for the low-dose group (P = 0.012 by the log-rank test). At 24 months the estimated survival rates were 27 percent for the standard-treatment group and 34 percent for the low-dose group (P = 0.033). In both groups, 82 percent of the subjects had another opportunistic infection, and the length of time to that infection was similar in the two groups (P = 0.56 by the log-rank test). CD4 T-lymphocyte counts improved transiently in both groups, and serum levels of HIV antigen decreased in the subjects with antigenemia. The hemoglobin level declined to less than 5 mmol per liter (80 g per liter) in 101 subjects in the standard-treatment group and in 77 in the low-dose group (39 vs. 29 percent, P = 0.0009 by the log-rank test). The neutrophil count declined to less than 0.750 x 10(9) per liter in 134 subjects in the standard-treatment group and in 96 in the low-dose group (51 vs. 37 percent, P = 0.0001). CONCLUSIONS. The reduced daily dose of zidovudine used in this study was at least as effective as the standard dose and was less toxic; however, with the use of a four-week induction period with a high dose followed by low-dose treatment, severe anemia and neutropenia were common complications of treatment with zidovudine.

Source Information

University of Miami School of Medicine, Department of Medicine, FL 33101.

This article has been cited by other articles:

• Rhee, M. S., Greenblatt, D. J. (2008). Pharmacologic Consideration for the Use of Antiretroviral Agents in the Elderly. J Clin Pharmacol 48: 1212-1225 [Abstract] [Full Text]  
• Orkin, C., Stebbing, J., Nelson, M., Bower, M., Johnson, M., Mandalia, S., Jones, R., Moyle, G., Fisher, M., Gazzard, B. (2005). A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). J Antimicrob Chemother 55: 246-251 [Abstract] [Full Text]  
• Albert, J. M, Yun, H. (2001). Statistical advances in AIDS therapy trials. Stat Methods Med Res 10: 85-100 [Abstract]  
• Karp, C. L., Scott, I. U., Chang, T. S., Pflugfelder, S. C. (1996). Conjunctival Intraepithelial Neoplasia: A Possible Marker for Human Immunodeficiency Virus Infection?. Arch Ophthalmol 114: 257-261 [Abstract]  
• Owens, D. K., Nease, R. F. Jr, Harris, R. A. (1996). Cost-effectiveness of HIV Screening in Acute Care Settings. Arch Intern Med 156: 394-404 [Abstract]  
• Freedberg, K. A., Hardy, W. D., Holzman, R. S., Tosteson, A. N.A., Craven, D. E. (1996). Validating Literature-based Models with Direct Clinical Trial Results: The Cost-Effectiveness of Secondary Prophylaxis for PCP in AIDS Patients. Med Decis Making 16: 29-35 [Abstract]  
• Kinloch-de Loes, S., Hirschel, B. J., Hoen, B., Cooper, D. A., Tindall, B., Carr, A., Saurat, J.-H., Clumeck, N., Lazzarin, A., Mathiesen, L., Raffi, F., Antunes, F., von Overbeck, J., Luthy, R., Glauser, M., Hawkins, D., Baumberger, C., Yerly, S., Perneger, T. V., Perrin, L. (1995). A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection. NEJM 333: 408-413 [Abstract] [Full Text]  
• Bozzette, S. A., Kanouse, D. E., Berry, S., Duan, N., R, , Gocke, D. J., Marlowe, S. I., Pottage, J. C. Jr, Follansbee, S. E., Remick, S., Klimas, N., Jensen, P., Henry, D. H., Olson, R., Turner, P. A., Lalezari, J. P., Phair, J., Pollard, R., Pierce, P. F., Saravolatz, L. D., Cohen, S., Cate, T., Pegram, P. S., Spotkov, J., Carey, J. T., Perez, G., Pettinelli, C., DownesLeGuin, T., Hill, D., Edwards, C., Mazel, R., Hays, R., Stewart, A., Soo, W., Salgo, M., Anthony, M., Dixon, D., Myers, M. (1995). Health Status and Function With Zidovudine or Zalcitabine as Initial Therapy for AIDS: A Randomized Controlled Trial. JAMA 273: 295-301 [Abstract]  
• Forseter, G., Joline, C., Wormser, G. P. (1994). Tolerability, Safety, and Acceptability of Zidovudine Prophylaxis in Health Care Workers. Arch Intern Med 154: 2745-2749 [Abstract]  
• Volberding, P. A., Lagakos, S. W., Grimes, J. M., Stein, D. S., Balfour, H. H. Jr, Reichman, R. C., Bartlett, J. A., Hirsch, M. S., Phair, J. P., Mitsuyasu, R. T., Fischl, M. A., Soeiro, R., the AIDS Clinical Trials Group of the National Ins, , Pettinelli, C. B., Martinez, A. I., Liou, S.-H., Henry, K., Simpson, M., DePaolis-Jones, A., Hewitt, R. G., Blair, D. C., Packard, M. V., Fowler, C., Crumpacker, C. S., Allan, J. D., Fitch, H. F., Dybeck, K., Coleman, R., Jacobson, M., Phair, J. P., Murphy, R., Benson, C., Hardy, W. D., Chafey, S. A., Kruger, S., Reese, J., Dale, E., Harris, C., Steigbigel, N., Becker, R. L., Rexroad, V. E., Feinberg, J. E., Spector, S. A., Richman, D. D., Snyder, R., Merigan, T. C. Jr, Fessel, J., Katzenstein, D., Zachary, J. A., Mushatt, D. M., Hyslop, N. E. Jr, Collier, A. C., Corey, L., Coombs, R. W., Para, M. F., Fass, R. J., Whitacre, C., Sacks, H. S., Mildvan, D., Mendoza, H., Fife, K., Powderly, W. G., Gelb, L. D., Klebert, M., Leedom, J. M., Liggins, M., Quesada, N., Wong, B., Brinkdopke, J., Hoelle, M., Gocke, D. J., McAuliffe, V. J., Valentine, F. T., Dowling, J., Wallace, M., PaulJarrett, V., Cargill, V., McKinley, G. F., Grieco, M. H., Polsky, B., Brown, D. C., van der Horst, C., Fiscus, S., Ragan, D., Cheeseman, S. H., Fairchild, P. G., Lai, K. K., Ho, M., McMahon, D., Armstrong, J. A., Eyster, M. E., Ehmann, W. C., Irwin, D., Steigbigel, R. T., Fuhrer, J., Tenzler, R., Ponticello, L., Giordano, M. F., Murray, H. W. (1994). The Duration of Zidovudine Benefit in Persons With Asymptomatic HIV Infection: Prolonged Evaluation of Protocol 019 of the AIDS Clinical Trials Group. JAMA 272: 437-442 [Abstract]  
• Sande, M. A., Carpenter, C. C. J., Cobbs, C. G., Holmes, K. K., Sanford, J. P., the National Institute of Allergy and Infectious D, , Sande, M. A., Carpenter, C. C. J., Cobbs, C. G., Coombs, R. W., Fleming, T. R., Holmes, K. K., Denison, R., Gail, M. H., Greaves, W. L., Hirsch, M. S., Luskin-Hawk, R., Mildvan, D., Nelson, C. A., Phair, J. P., Sanford, J. P., Schooley, R., Torres, R. G., Vazquez, R., Deyton, L., Jermano, J., Koziol, J., Pettinelli, C., Katz, D. (1993). Antiretroviral Therapy for Adult HIV-lnfected Patients: Recommendations From a State-of-the-Art Conference. JAMA 270: 2583-2589 [Abstract]  
• Saag, M. S., Emini, E. A., Laskin, O. L., Douglas, J., Lapidus, W. I., Schleif, W. A., Whitley, R. J., Hildebrand, C., Byrnes, V. W., Kappes, J. C., Anderson, K. W., Massari, F. E., Shaw, G. M., The 661 Working Group L-697, (1993). A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase. NEJM 329: 1065-1072 [Abstract] [Full Text]  
• Cooper, D. A., Gatell, J. M., Kroon, S., Clumeck, N., Millard, J., Goebel, F.-D, Bruun, J. N., Stingl, G., Melville, R. L., Gonzalez-Lahoz, J., Stevens, J. W., Fiddian, A. P., The European-Australian Collaborative Group, (1993). Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic Millimeter. NEJM 329: 297-303 [Abstract] [Full Text]  
• Henry, D. H., Beall, G. N., Benson, C. A., Carey, J., Cone, L. A., Eron, L. J., Fiala, M., Fischl, M. A., Gabin, S. J., Gottlieb, M. S., Galpin, J. E., Groopman, J. E., Hooton, T. M., Jemsek, J. G., Levine, R. L., Miles, S. A., Rinehart, J. J., Rios, A., Robbins, W. J., Ruckdeschel, J. C., Smith, J. A., Spruance, S. L., Starrett, B., Toney, J., Zalusky, R., Abels, R. I., Bryant, E. C., Larholt, K. M., Sampson, A. R., Rudnick, S. A. (1992). Recombinant Human Erythropoietin in the Treatment of Anemia Associated with Human Immunodeficiency Virus (HIV) Infection and Zidovudine Therapy: Overview of Four Clinical Trials. ANN INTERN MED 117: 739-748 [Abstract]  
• Koch, M. A., Volberding, P. A., Lagakos, S. W., Booth, D. K., Pettinelli, C., Myers, M. W. (1992). Toxic Effects of Zidovudine in Asymptomatic Human Immunodeficiency Virus-Infected Individuals With CD4+ Cell Counts of 0.50x109/L or Less: Detailed and Updated Results From Protocol 019 of the AIDS Clinical Trials Group. Arch Intern Med 152: 2286-2292 [Abstract]  
• Chaisson, R. E., Keruly, J., Richman, D. D., Moore, R. D. (1992). Pneumocystis Prophylaxis and Survival in Patients With Advanced Human Immunodeficiency Virus Infection Treated With Zidovudine. Arch Intern Med 152: 2009-2013 [Abstract]  
• McLeod, G. X., Hammer, S. M. (1992). Zidovudine: Five Years Later. ANN INTERN MED 117: 487-501 [Abstract]  
• Gelber, R. D., Lenderking, W. R., Cotton, D. J., Cole, B. F., Fischl, M. A., Goldhirsch, A., Testa, M. A. (1992). Quality-of-Life Evaluation in a Clinical Trial of Zidovudine Therapy in Patients with Mildly Symptomatic HIV Infection. ANN INTERN MED 116: 961-966 [Abstract]  
• Drusano, G. L., Yuen, G. J., Lambert, J. S., Seidlin, M., Dolin, R., Valentine, F. T. (1992). Relationship between Dideoxyinosine Exposure, CD4 Counts, and p24 Antigen Levels in Human Immunodeficiency Virus Infection: A Phase I Trial. ANN INTERN MED 116: 562-566 [Abstract]  
• Meng, T.-C., Fischl, M. A., Boota, A. M., Spector, S. A., Bennett, D., Bassiakos, Y., Lai, S., Wright, B., Richman, D. D. (1992). Combination Therapy with Zidovudine and Dideoxycytidine in Patients with Advanced Human Immunodeficiency Virus Infection: A Phase I/II Study. ANN INTERN MED 116: 13-20 [Abstract]  
• Moore, R. D., Creagh-Kirk, T., Keruly, J., Link, G., Wang, M.-C., Richman, D., Chaisson, R. E., Zidovudine Epidemiology Study Group, (1991). Long-term Safety and Efficacy of Zidovudine in Patients With Advanced Human Immunodeficiency Virus Disease. Arch Intern Med 151: 981-986 [Abstract]  
• (1990). LOW-DOSE ZIDOVUDINE IS CONFIRMED EFFECTIVE IN EARLY AIDS. JWatch General 1990: 4-4 [Full Text]